Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and in vitro anti-tumoral activity

Journal of Controlled Release

Volumn 83, Issue 2, 2002, Pages 273-286

  Fonseca, Cristina ^a   Simões, Sérgio ^a,b   Gaspar, Rogério ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Anti tumoral activity; Nanoparticles; Nanoprecipitation; Paclitaxel; Poly(lactide co glycolide acid)

Indexed keywords

ANTINEOPLASTIC AGENT; CREMOPHOR; NANOPARTICLE; PACLITAXEL; POLYGLACTIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ELECTRICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LUNG SMALL CELL CANCER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SIDE EFFECT;

CHEMISTRY, PHYSICAL; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LACTIC ACID; NANOTECHNOLOGY; PACLITAXEL; POLYGLYCOLIC ACID; POLYMERS; TUMOR CELLS, CULTURED;

EID: 0037020525     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00212-2     Document Type: Article

References (62)

1. Ishitobi M., Shin E., Kikkawa N. Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weakly paclitaxel. Int. J. Clin. Oncol. 6:(1):2001;55-58.
2. Thigpen J.T. Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin. Oncol. 27:(3 Suppl. 7):2000;11-16.
3. Chang A.Y., Rubins J., Asbury R., Boros L., Hui L.F. Weekly paclitaxel in advanced non-small cell lung cancer. Semin. Oncol. 28:(4 Suppl. 14):2001;10-13.
4. Spencer C.M., Faulds D. Paclitaxel - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs. 48:(5):1994;794-847.
5. Panchagnula R. Pharmaceutical aspects of paclitaxel. Int. J. Pharm. 172:(1-2):1998;1-15.
6. Weiss R.B., Donehower R.C., Wiernik P.H., et al. Hypersensitivity reactions from Taxol. J. Clin. Oncol. 8:(7):1990;1263-1268.
7. Waugh W.N., Trissel L.A., Stella V.J. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am. J. Hosp. Pharm. 48:(7):1991;1520-1524.
8. Dorr R.T. Pharmacology and toxicology of Cremophor EL diluent. Ann. Pharmacother. 28:1994;S11-S14.
9. Szebeni J., Mugia F.M., Alving C.R. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl. Cancer Inst. 90:(4):1998;300-306.
10. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer. 37:(13):2001;1590-1598.
11. Tarr B.D., Sambandan T.G., Yalkowsky S.H. A new parenteral emulsion for the administration of Taxol. Pharm. Res. 4:(2):1987;162-165.
12. Ludenberg B.B. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J. Pharm. Pharmacol. 49:(1):1997;16-21.
13. Sharma A., Straubinger R.M. Novel taxol formulations: preparation and characterization of Taxol containing liposomes. Pharm. Res. 11:(6):1994;889-896.
14. Crosasso P., Ceruti M., Brusa P., Arpicco S., Dosio F., Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Control. Relase. 63:(1-2):2000;19-30.
15. Campbel R.B., Balasubramanian S.V., Straubinger R.M. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. J. Pharm. Sci. 90:(8):2001;1091-1105.
16. Bartoli M.H., Boitard M., Fessi H., Beriel H., Devissaguet J.P., Picot F., Puisieux F. In vitro and in vivo antitumoral activity of free and encapsulated Taxol. J. Microencapsul. 7:(2):1990;191-197.
17. Sharma D., Chelvi T.P., Kaur J., Chakravorty K., De T.K., Maitra A., Ralham R. Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer chemotherapy. Oncol. Res. 8:(7-8):1996;281-286.
18. Chen D.B., Yang T.Z., Lu W.L., Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. 49:(11):2001;1444-1447.
19. Feng S.S., Huang G.F., Mu L. Nanospheres of biodegradable polymers: a system for clinical administration of an anticancer drug paclitaxel (Taxol®) Ann. Acad. Med. Singapore. 29:(5):2000;633-639.
20. Feng S.S., Huang G.F. Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers. J. Control. Release. 71:2001;53-69.
21. Wang Y.M., Sato H., Adachi I., Hirikoshi I. Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, Taxol. Chem. Pharm. Bull. 44:(10):1996;1935-1940.
22. Sato H., Wang Y.M., Adachi I., I Hirikoshi H. Pharmacokinetic study of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate after targeted delivery to the lung in mice. Biol. Pharm. Bull. 19:(12):1996;1596-1601.
23. Mu L., Feng S.S. Fabrication, characterization and in vitro release of paclitaxel (Taxol®) loaded poly(lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J. Control. Release. 76:(3):2001;239-254.
24. Liggins R.T., M Burt H. Paclitaxel loaded poly(L-lactic acid) microspheres: properties of microspheres made with low molecular weight polymers. Int. J. Pharm. 222:(1):2001;19-33.
25. Couvreur P., Kante B., Lenaerts V., Scailteur V., Roland M., Speiser P. Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J. Pharm. Sci. 69:(2):1980;199-202.
26. Rolland A. Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline. Int. J. Pharm. 54:(2):1989;113-121.
27. Leroux J.-C., Doelker E., Gurny R. The use of drug-loaded nanoparticles in cancer chemotherapy. Benita S., Microencapsulation: Methods and Industrial Applications. 1996;535-575 Marcel Dekker, New York.
28. Monsky W.L., Fukumura D., Gohongi T., Ancukiewcz M., Weich H.A., Torchilin V.P., Yuan F., Jain R.K. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 59:(16):1999;4129-4135.
29. Bennis S., Chapey C., Couvreur P., Robert J. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant cells in culture. Eur. J. Cancer. 30A:(1):1994;89-93.
30. Rowinsky E.K., Donehower R.C. Drug therapy: paclitaxel - review article. New Engl. J. Med. 332:(15):1995;1004-1014.
31. Magenheim B., Benita S. Nanoparticle characterization: a comprehensive physicochemical approach. STP Pharma Sci. 1:(4):1991;221-241.
32. Fessi H., Puisieux F., Devissaguet J.Ph., Ammoury N., Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55:(1):1989;R1-R4.
33. Anderson J.M., Shive M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Del. Rev. 28:1997;5-24.
34. Moreira J.N., Hansen C.B., Gaspar R., Allen T.M. A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochim. Biophys. Acta. 1514:(2):2001;303-317.
35. Mosmann T. Rapid calorimetric assay for cellular growth and survival: application of proliferation and cytotoxicity assay. J. Immunol. Methods. 65:(1-2):1983;55-63.
36. Raymond E., Hanauske A., Faivre S., et al. Effects of prolonged versus short-term exposure paclitaxel (taxol) on human tumor colony-forming units. Anti-Cancer Drugs. 8:(4):1997;379-385.
37. Liebmann J., Cook J.A., Lipschultz C., Teague D., Fisher J., Mitchell J.B. Cytotoxic studies of paclitaxel (Taxol®) in human tumor cell lines. Br. J. Cancer. 68:(6):1993;1104-1109.
38. Liebmann J., Cook J.A., Mitchell J.B. Cremophor EL solvent for paclitaxel and toxicity. Lancet. 342:(8884):1993;1428.
39. Liebmann J., Cook J.A., Lipschultz C., Teague D., Fisher J., Mitchell J.B. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother. Pharmacol. 33:(4):1994;331-339.
40. Vauthier-Holtzsherer C., Benabbou S., Spenlehauer G., Veillard M., Couvreur P. Methodology for the preparation of ultra-dispersed polymer systems. STP Pharma Sci. 1:(2):1991;109-116.
41. Alléman E., Gurny R., Leroux J.C. Biodegradable nanoparticles of poly(lactic acid) and poly(lactic acid-co-glycolic acid) for parenteral administration. Lieberman H.A., Rieger M.M., Barker G.S., Pharmaceutical Dosage Forms. Vol. 3:1998;163-193 Marcel Dekker, New York.
42. Velde D.G., Georg G.I., Grunewald G.L., Gunn C.W., Mitscher L.A. 'Hydrophobic collapse' of Taxol and Taxotere solution conformations in mixtures of water and organic solvent. J. Am. Chem. Soc. 115:1993;11650-11651.
43. Balasubramanian S.V., Alderfer J.L., Straubinger R.M. Solvent- and Concentration-dependent molecular interactions of Taxol (Paclitaxel). J. Pharm. Sci. 83:(10):1994;1470-1476.
44. Quintanar-Guerrero D., Allémann E., Fessi H., Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug. Dev. Ind. Pharm. 24:(12):1998;1113-1128.
45. Sánchez A., Vila-Jato J.L., Alonso M.J. Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporin A. Int. J. Pharm. 99:(2-3):1993;263-273.
46. Chacón M., Berges L., Molpeceres J., Aberturas M.R., Guzman M. Optimized preparation of poly(D,L lactic-co-glycolic) acid microspheres and nanospheres for oral administration. Int. J. Pharm. 141:(1-2):1996;81-91.
47. Maaßen S., Fattal E., Müller R.H., Couvreur P. Cell cultures for the assessment of toxicity and uptake of polymeric particulate drug carriers. STP Pharma Sci. 3:(1):1993;11-22.
48. Bodmeier R., Maincent P. Polymeric dispersions as drug carriers. Lieberman H.A., Rieger M.M., Banker G.S., Pharmaceutical Dosage Forms: Disperse Systems. Vol. 3:1998;87-127 Marcel Dekker, New York.
49. Mauduit J., Vert M. Les polymères à base d'acides lactiques et glycolique at la délivrance contrôlée des principes actifs. STP Pharma Sci. 3:(3):1993;197-212.
50. Lacasse F.X., Filion M.C., Phillips N.C., Escher E., McMullen J.N., Hildgen P. Influence of surface properties at biodegradable microspheres surfaces: effects on plasma protein adsorption and phagocytosis. Pharm. Res. 15:(2):1998;312-317.
51. Marshal-Heussler L., Fessi H., Devissaguet J.P., Hoffman M., Maicent P. Colloidal drug delivery systems for the eye. A comparison of the efficacy of three different polymers: polyisobutylcyanoacrylate, poly(lactic-co-glycolic acid), poly-epsilon-caprolacton. STP Pharma Sci. 2:(1):1992;98-104.
52. Niwa T., Takeuchi H., Kunou N., Kawashima Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J. Control. Release. 25:(1-2):1993;89-98.
53. Govender T., Stolnik S., Garnett M.C., Illum L., Davis S.S. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J. Control. Release. 57:(2):1999;171-185.
54. Stolnik S., Davies M.C., Illum L., Davis S.S., Boustta M., Vert M. The preparation of sub-200 nm biodegradable colloidal particles from poly (β-malic acid-cobenzyl malate) copolymers and their surface modification with poloxamer and poloxamine surfactants. J. Control. Release. 30:(1):1994;57-67.
55. Muller R.H., Wallis K.H. Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. Int. J. Pharm. 89:(1):1993;25-31.
56. Wang Y.M., Sato H., Horikoshi I. In vitro and in vivo evaluation of taxol release from poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate and degradation of the microspheres. J. Control. Release. 49:(2-3):1997;157-166.
57. Lopes N.M., Adams E.G., Pitts T.W., Bhuyan B.K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 32:(3):1993;235-242.
58. Gaspar M.M., Blanco D., Cruz M.E.M., Alonso M.J. Formulation of L-asparaginase-loaded poly(lactide-co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release. J. Control. Release. 52:(1-2):1998;53-62.
59. Sanders L.M., Kell B.A., McRae G.I., Whitehead G.W. Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer. J. Pharm. Sci. 75:(4):1986;356-360.
60. Slichenmyer W.J., Von Hoff D.D. Taxol: a new and effective anti-cancer drug. Anti-Cancer Drugs. 2:1991;519-530.
61. Dordunoo S.K., Burt H.M. Solubility and stability of taxol: effects of buffers and cyclodextrins. Int. J. Pharm. 133:(1-2):1996;191-201.
62. Némati F., Dubernet C., Colin de Vérdiere A., Poupon M.F., Treupel-Acar L., Puisieux F., Couvreur P. Some parameters influencing cytotoxicity of free doxorubicin and doxorubicin-loaded nanoparticles in sensitive and multidrug resistant leukemic murine cells: incubation time, number of nanoparticles per cell. Int. J. Pharm. 102:(1-3):1994;55-62.